Hitoshi Hirakata
Nihon University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hitoshi Hirakata.
Urologia Internationalis | 2012
Daisaku Hirano; Yasuhiro Okada; Yusuke Nagane; K. Satoh; Junichi Mochida; Yataroh Yamanaka; Hitoshi Hirakata; Kenya Yamaguchi; Nozomu Kawata; Satoru Takahashi; Akihiro Henmi
Objectives: To elucidate clinicopathological risk factors for intravesical recurrence (IVR) in patients undergoing nephroureterectomy for upper urinary tract urothelial carcinoma (UUT-UC). Methods: We identified a study population of 151 consecutive patients without previous or concurrent bladder cancer who underwent nephroureterectomy for UUT-UC. IVR was assessed in relation to tumor location, size, and multifocality, operation modality and time, stage, grade, lymphovascular invasion, regional lymph node metastasis, preoperative urinary cytology, and perioperative chemotherapy. The median follow-up time was 24 months. Results: Of 151 patients, 51 (34%) developed IVR after nephroureterectomy, and 50 (98%) of the patients presented with IVR within 2 years. Tumor multifocality and site (located in ureter) were determined as risk factors for IVR by univariate analysis. In a multivariate analysis, only tumor multifocality (relative risk: 4.024, p = 0.001) was an independent predictor of IVR. Ten-year cancer-specific survival rates for the patients with and without IVR were 68 and 52%, respectively (p = 0.06). Conclusions: Tumor multifocality is a significant risk factor in developing IVR after surgery for UUT-UC. These results indicate that despite most IVR occurring within 2 years of treatment, it is necessary to follow such patients more closely using cystoscopy. However, IVR is unlikely to indicate a poorer prognosis.
International Journal of Urology | 2008
Nozomu Kawata; Yusuke Nagane; Kenya Yamaguchi; Taketo Ichinose; Hitoshi Hirakata; Satoru Takahashi
Aim: Symptomatic renal cell carcinoma (RCC) is well known to have a characteristic behavior. We therefore evaluated the impact of systemic symptoms on the prognosis of RCC.
International Journal of Urology | 1997
Daisaku Hirano; Yukie Takimoto; Tadao Yamamoto; Hitoshi Hirakata; Nozomu Kawata
Background We conducted ultrastructural studies to clarify the fine structure of penile plaques and adjacent corpora cavernosa, and the causative basis for the process, in Peyronies disease.
International Journal of Urology | 2000
Nozomu Kawata; Hitoshi Hirakata; Humikazu Yuge; Masahito Kodama; Shuji Sugimoto; Hiroki Yagasaki; Junichi Mochida; Kei Fujimura; Yukie Takimoto
The purpose of this study was to demonstrate the benefits of cytoreductive surgery for renal cell carcinomas that also involve the liver. Between 1994 and 1997, four patients with renal cell carcinoma with liver involvement were surgically treated with nephrectomy and hepatectomy. Two of them underwent a simultaneous hepatectomy and nephrectomy (group 1), and the remaining two patients underwent a hepatectomy after a nephrectomy and had a diagnosis of postoperative recurrence (group 2). Two patients, one from each group, died of multiple bone metastasis and lung metastasis 30 months and 12 months after the hepatectomy; the second patient from group 1 died 40 months after the first operation due to gastrointestinal hemorrhaging. The second patient from group 2 displayed no evidence of recurrence 18 months after the second surgical procedure. The survival rates for these patients were 66% and 33% at 1 and 3 years, respectively. Autopsy studies revealed that one patient from group 2 had a local recurrence in the liver while the other two patients from group 1 did not. Our results suggested that a progressive approach may therefore be useful for patients demonstrating renal cell carcinoma where there is liver involvement.
The Japanese Journal of Urology | 1999
Yukie Takimoto; Masahito Kodama; Shuuji Sugimoto; Takamasa Hamada; Takuro Fuse; Nozomu Kawata; Hitoshi Hirakata; Hiromi Hosokawa
17 cases of patients with diabetes mellitus who had urinary frequency symptom for which anti-cholinergic agents proved ineffective were given Sarpogrelate Hydrochloride (Anplag), a selective 5-HT 2 receptor antagonist. Efficacy was judged using IPSS and QOL scores after 2 weeks medications, these showed that all cases had improved their urinary frequency during the days as well as the night. This was especially true for the QOL score. One time urinary volume markedly increased, but there was no statistical significance after medication in maximum flow rate and residual urine. At the same time, a separate group of 14 mainly BPH cases did not improve entirely. It is believed that reaction in the detrusor muscle with hyperreflexia of diabetes mellitus patients can reach 5-HT, and its reaction is believed to reach via the 5-HT 2 receptor. This paper is a first clinical report of making use of 5-HT 2 antagonist as hyperactive detrusor on diabetes mellitus patients.
International Journal of Urology | 2001
Nozomu Kawata; Hiroki Yagasaki; Humikazu Yuge; Yuji Nakanoya; Kei Fujimura; Shuji Sugimoto; Hitoshi Hirakata; Yukie Takimoto
This study was conducted in order to clarify whether histopathologic analysis of factor thymidine phosphorylase (TP) and Factor VIII could be a useful predictor of postoperative recurrence in localized renal cell carcinoma. Therefore, the relationship between tumor infiltrated lymphocytes (TIL) and both TP and Factor VIII was studied.
International Journal of Urology | 2006
Takahiko Hachiya; Taketo Ichinose; Hitoshi Hirakata; Nozomu Kawata; Kiyoki Okada; Yukie Takimoto
Objective: This study attempts to determine whether prostate‐specific antigen (PSA) failure following radical retropubic prostatectomy (RRP) affects patients’ long‐term overall survival.
International Journal of Urology | 2006
Nozomu Kawata; Takumi Igarashi; Taketo Ichinose; Hitoshi Hirakata; Takahiko Hachiya; Yukie Takimoto; Masahiro Ogawa
Abstract We studied contrast‐enhanced ultrasound (CEU) for recurrence of renal cell carcinoma (RCC) at the contralateral kidney during postoperative follow up of localized renal cell carcinoma. CEU successfully detected all recurring cases, despite the fact that 5/6 cases were observed using conventional ultrasound; the remaining one case was not detected using conventional ultrasound. CEU using Levovisto successfully revealed renal tumors as RCC. Lesions were diagnosed as cystic renal tumors by Bosniac classification, and pathological findings demonstrated RCC, in accordance with the prior tumor.
Journal of Integrative Oncology | 2015
Nozomu Kawata; Tomohiro Igarashi; Kenya Yamaguchi; Hitoshi Hirakata; Satoru Takahashi
We experienced a case of renal cell carcinoma in congenital solitary kidney of an 80-year old male with a status post bypass grafts of coronary arteries and advanced heart failure. Incidentally we identified a left renal cell carcinoma 60mm in diameter, and an aneurysm of left renal artery. According to the R.E.N.A.L. Nephrometry Score, the tumor had 2-2-3-2 and total 9 points. Preoprerative e-GFR was 62.1 ml/min. He underwent open nephron sparing surgery by using intestinal forceps for kidney clamp instead of vascular clamp. Following an uneventful postoperative course, e-GFR became 45.6 ml/min. No recurrence was observed at 25 months after surgery. Even though laparoscopic partial nephrectomy is the gold standard for small renal mass, open procedure is still a mainstay for imperative cases.
Scandinavian Journal of Urology and Nephrology | 2014
Daisaku Hirano; Ryo Hasegawa; K. Satoh; Junichi Mochida; Yataroh Yamanaka; Hitoshi Hirakata; Kenya Yamaguchi; Shuji Sugimoto; Nozomu Kawata; Satoru Takahashi
Abstract Objective. The aim of this study was to prospectively verify the relationship between the clinical efficacies of secondary hormone therapy for castration-resistant prostate cancer (CRPC) following first line hormone therapy and neuroendocrine differentiation (NED). Material and methods. Forty-six consecutive patients with CRPC following first line hormone therapy who were treated with flutamide as secondary hormone therapy were prospectively assessed with a median follow-up of 21 months. Serum chromogranin A (CgA), as a marker of NED, was measured using an immunoradiometric assay. Results. Of the 46 patients, 22 (48%) responded to the secondary hormone therapy as a 50% or more reduction from baseline prostate-specific antigen (PSA) with a median response duration of 9.2 months. The PSA response group was correlated with significantly favorable cancer-specific survival (CSS) (92% vs 59% at 5 years, p = 0.0146) compared with the non-response group. Above-normal CgA levels at study entry were detected in 15 patients (33%), but no association with CSS was identified. Data on CgA kinetics were available in 35 patients. The CgA levels before and at 3 months during the treatment were similar. However, eight patients (23%) with an increase in CgA level of a quarter or more from baseline had a tendency for worse CSS (63% vs 84% at 5 years, p = 0.0507) compared with the remaining patients. Conclusion. Within limitations, in this study secondary hormone therapy with flutamide was effective for CRPC following first line hormone therapy. The above-normal CgA level in the first hormone resistance phase is mostly unrelated to prognosis. However, some patients with a remarkable increase in CgA in a short duration may have an unfavorable prognosis caused by NED as well.